Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.
Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.
复制标题
DOI：
10.1089/cap.2010.0134
复制
发表时间：
2011-12
影响因子：
1.9
通讯作者：
Z. Tobiásová;Klaas H. B. van der Lingen;L. Scahill;J. Leckman;Yan Zhang;W. Chae;James T. McCracken;C. McDougle;B. Vitiello;E. Tierney;M. Aman;L. E. Arnold;L. Katsovich;P. J. Hoekstra;F. Volkmar;Alfred L. M. Bothwell;I. Kawikova
中科院分区：
文献类型：
--
作者：
Z. Tobiásová;Klaas H. B. van der Lingen;L. Scahill;J. Leckman;Yan Zhang;W. Chae;James T. McCracken;C. McDougle;B. Vitiello;E. Tierney;M. Aman;L. E. Arnold;L. Katsovich;P. J. Hoekstra;F. Volkmar;Alfred L. M. Bothwell;I. Kawikova
利培酮已被证明可以改善自闭症儿童的严重行为问题。在这里，我们询问利培酮相关的改善是否与这些受试者血清中炎症分子浓度的变化有关。通过对21名未接受药物治疗的自闭症受试者与15名健康对照者的31种炎症标志物进行初步分析，确定了7种分子值得进一步评估：表皮生长因子（EGF）、干扰素-γ（IFN-γ）、白细胞介素（IL）-13，IL-17、单核细胞趋化蛋白-1（MCP-1）、IL-1和IL-1受体拮抗剂。然后在参与双盲临床试验的不同受试者组和扩大的健康受试者组中确定这些标志物的血清浓度。在第一次分析中，将基线访视时从自闭症受试者获得的样本与安慰剂（n=37）或利培酮（n=40）治疗8周后的访视进行比较。利培酮组和安慰剂组的细胞因子浓度在8周内保持稳定。在第二项分析中，我们进一步探索了无药物治疗的自闭症受试者（n=77）和健康对照组（独立招募; n=19）之间的差异。与健康对照组（75 pg/mL，n=19; p<0.05）相比，自闭症受试者（中位数=103 pg/mL，n=75）的EGF血清水平升高，与对照组（9.8 pg/mL，n = 19; p=0.0003）相比，自闭症受试者（中位数=0.8 pg/mL，n = 77）的IL-13水平降低。这些变化与用于诊断自闭症的标准化措施无关。总之，利培酮诱导的孤独症患者的临床改善与测量的血清炎症标志物的变化无关。EGF和IL-13水平的改变是否在自闭症的发病机制或表型中起作用需要进一步研究。
Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-γ (IFN-γ), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n=37) or risperidone (n=40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n=77) and healthy controls (recruited independently; n=19). Serum levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003). These changes did not correlate with standardized measures used for a diagnosis of autism. In summary, risperidone-induced clinical improvement in subjects with autism was not associated with changes in the serum inflammatory markers measured. Whether altered levels of EGF and IL-13 play a role in the pathogenesis or phenotype of autism requires further investigation.